"These studies will [determine the optimal clinical dosing of long-acting Leronlimab]...and lay the foundation for testing long-acting Leronlimab clinically as a PREP individuals at high-risk of acquiring HIV via sexual transmission."
Perhaps, l am reading too much into this statement...butt, it sounds to me like this is a foregone conclusion...and its just a question of metrics...and the time necessary as noted... to determine as always in science...failing leads to success.